ProCE Banner Activity

Identifying and Managing Delayed Adverse Events Associated With CAR T-Cell Therapy

Clinical Thought
CAR T-cell therapies can meaningfully improve outcomes for patients with certain hematologic cancers, but these treatments can cause a unique spectrum of adverse events to which physicians must be attuned. In this commentary, an expert describes key considerations in managing delayed toxicities associated with CAR T-cell therapy, including cytopenias and infections.

Released: August 05, 2021

Expiration: August 04, 2022

Share

Faculty

Caron Jacobson

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Caron Jacobson, MD

Associate Professor of Medicine
Harvard Medical School
Medical Director, Immune Effector Cell Therapy Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Caron A. Jacobson, MD, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb/Celgene, Bluebird Bio, Kite, Lonza, Nkarta, Novartis, and Precision Biosciences and funds for research support from Kite.